Related Experiment Video
Updated: Jan 7, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
Diagnostic value of RAS mutations in Bethesda category IV thyroid nodules: a systematic review and meta-analysis
Jiayue Sun1, Yilin Hou1, Chengfei Sun2
1Department of Ultrasound, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China.
Objectives:
Thyroid nodules classified as Bethesda category IV cannot be diagnosed with fine-needle aspiration. RAS mutations have been linked to thyroid cancer, although it is still unclear if they are useful as a pre-operative molecular screening for this particular subgroup. In order to assess the diagnostic accuracy (sensitivity, specificity, AUC, etc.) of RAS mutations in identifying malignancy among Bethesda IV nodules and to ascertain whether this can consistently direct clinical decision-making and minimize non-essential interventions, we carried out a systematic review and meta-analysis using postoperative histopathology as the reference standard.
Methods:
A literature search of the PubMed, Embase, Cochrane Library, Web of Science and OVID databases was conducted. In all of the included studies, the diagnostic accuracy of RAS was compared with that of postoperative pathology, which was used as a standard. Data were pooled, and the sensitivity, specificity, area under the curve (AUC), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated to estimate the accuracy of RAS.
Results:
A total of 10 studies were included after screening, comprising 913 cases of Bethesda Category IV nodules. Among them, there were 246 malignant lesions and 667 benign lesions. The pooled sensitivity of RAS mutations was 0.35 (95% CI, 0.29-0.41), and the specificity was 0.93 (95% CI, 0.90-0.95). The positive likelihood ratio was 3.46 (95% CI, 1.94-6.18), the negative likelihood ratio was 0.73 (95% CI, 0.60-0.89), and the AUC was 0.7954. Heterogeneity testing showed p<0.05, I2 = 58.5%, indicating significant heterogeneity.
Conclusion:
RAS mutations have a moderate diagnostic value in the diagnosis of Bethesda Category IV thyroid nodules. Despite the presence of some heterogeneity, the detection of RAS mutations may be helpful in guiding clinical decision-making and management strategies.
Systematic Review Registration:
https://www.crd.york.ac.uk/prospero, identifier CRD42024608197.
Related Concept Videos
The Ras Gene
Ras is a...
Abnormal Proliferation

